SYRE — Spyre Therapeutics, Inc. | XLV Holdings | StockAdder

(SYRE)

Spyre Therapeutics, Inc.

Live chart and latest SYRE stock news.

Sector ETF → XLV Health Care Select

Chart powered byTradingView— professional charts for every trader.Try it free →

SYRE News

Quiver Quantitative

Spyre Therapeutics Announces $403 Million Public Offering of Common Stock

Apr 15, 2026 simplywall.st

Assessing Spyre Therapeutics (SYRE) Valuation After Recent Share Price Momentum And Premium P/B Multiple

Apr 14, 2026 timothysykes.com

SYRE Stock Jumps As Stifel Hikes Price Target To $92

Apr 13, 2026 Seeking Alpha

Spyre Therapeutics: Strong SPY001 Data Sets Up A Catalyst-Rich 2026 (NASDAQ:SYRE)

Apr 14, 2026 Stocktwits

SYRE Stock Marks Best Session In About 3 Years — Here’s Why

Apr 14, 2026 Investing.com

Raymond James initiates Spyre stock with strong buy rating

Apr 13, 2026 GuruFocus

Spyre Therapeutics (SYRE) Initiates $300 Million Stock Offering

Apr 13, 2026 StocksToTrade

SYRE Stock Jumps As Stifel Hikes Price Target To $92

Apr 13, 2026 Stock Titan

Spyre Therapeutics (NASDAQ: SYRE) seeks $300M via common stock offering; SPY001 shows strong Phase 2 topline

Apr 13, 2026 GuruFocus

Spyre Therapeutics (SYRE) Sees Significant Stock Surge

Apr 13, 2026 timothysykes.com

SYRE Stock Pops As Stifel Hikes Target Ahead Trial Catalysts

Apr 13, 2026 Stock Titan

Spyre moves to raise $300M, with room to expand the sale to $345M

Apr 13, 2026 GuruFocus

Spyre Therapeutics (SYRE) Sees Significant Price Surge

Apr 13, 2026 Stock Titan

Spyre Therapeutics (NASDAQ: SYRE) ends ATM prospectus, reports $741M cash

Apr 13, 2026 Seeking Alpha

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis - Slideshow (NASDAQ:SYRE) 2026-04-14